Immune Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Immune Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia [Phase 2]
Phase 2 study investigating zanubrutinib combined with eltrombopag as second-line therapy in adults with immune thrombocytopenia.
-
CLINICAL_TRIALS trial_result · 2022-05-02Clinical Trial Update: The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 trial evaluating the combination of iguratimod and danazol for steroid-resistant or relapsed immune thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 trial evaluating the combination of sitagliptin and danazol for steroid-resistant/relapse immune thrombocytopenia; current status un…
-
CLINICAL_TRIALS trial_result · 2022-04-26Clinical Trial Update: Herombopag + rhTPO in Severe Immune Thrombocytopenia [Phase 3]
Phase 3 trial update for Herombopag plus rhTPO in severe immune thrombocytopenia is reported with unknown status.
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy [Phase 2]
Phase 2 clinical trial investigating prednisone plus recombinant human thrombopoietin for immune thrombocytopenia in pregnancy; status curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Anti-BCMA CAR T-Cell Therapy for R/R ITP [Phase 2]
Phase 2 clinical trial update evaluating anti-BCMA CAR T-cell therapy for relapsed/refractory immune thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients [Phase 4]
Phase 4 trial update evaluating efficacy and safety of TPO receptor agonists in elderly patients with primary immune thrombocytopenia.
-
FDA approval · 2022-03-31FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for PROMACTA (eltrombopag olamine) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 clinical trial update evaluating efficacy and safety of iguratimod in steroid-resistant/relapsed immune thrombocytopenia.
-
FDA approval · 2022-02-10FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for NPLATE (romiplostim) from Amgen. This action updates the product’s labeling as described in …
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: A Study of Orelabrutinib in Patients With ITP [Phase 1, Phase 2]
Clinical trial update for orelabrutinib in immune thrombocytopenia (ITP) across Phase 1 and Phase 2.
-
CLINICAL_TRIALS withdrawal · 2021-10-22Clinical Trial Update: Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months [Phase 3]
Open-label Phase 3 trial evaluating avatrombopag in adults with immune thrombocytopenia has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia [Phase 2]
Phase 2 trial update evaluating the combination of ATRA and high-dose dexamethasone as first-line treatment for adult immune thrombocytopeni…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Atorvastatin in Management of Newly Diagnosed ITP [Phase 2, Phase 3]
Clinical trial update on atorvastatin for management of newly diagnosed immune thrombocytopenia (Phase 2/Phase 3).
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP [Phase 2]
Phase 2 clinical trial investigating orelabrutinib for refractory immune thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia [Phase 2]
Phase 2 clinical trial of eltrombopag in second-line adult primary immune thrombocytopenia has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP [Phase 4]
Phase 4 trial update on glycyrrhetinic acid combined with dexamethasone for newly diagnosed immune thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2021-03-30Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) [Phase 3]
A Phase 3 clinical trial evaluating LIV-GAMMA SN Inj. for efficacy and safety in adults with immune thrombocytopenia has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP) [Phase 2]
Open-label Phase 2 safety study for lusutrombopag in adults with chronic immune thrombocytopenia (ITP) has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-24Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) [Phase 2]
Phase 2 study of lusutrombopag (S-888711) in adults with immune thrombocytopenia (ITP) was terminated.
-
FDA approval · 2021-02-10FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)
FDA approved Amgen's supplemental application for NPLATE (romiplostim), approving changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2021-02-10Clinical Trial Update: The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia [Phase 2]
Phase 2 trial evaluating tacrolimus with high-dose dexamethasone as first-line therapy for adult immune thrombocytopenia; status currently u…
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 clinical trial investigating low-dose rituximab plus ATRA for steroid-resistant or relapsed immune thrombocytopenia.
-
FDA approval · 2020-11-23FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for NPLATE (romiplostim) from Amgen to expand its labeling.
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: A Study of ATRA in the Treatment of ITP [Phase 2]
Phase 2 clinical trial update on all-trans retinoic acid (ATRA) for immune thrombocytopenia (ITP).